Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.

Division of Gastroenterology, CHUV, Lausanne, Switzerland.
Gut (Impact Factor: 13.32). 05/1995; 36(4):539-43. DOI: 10.1136/gut.36.4.539
Source: PubMed

ABSTRACT To test the hypothesis that Helicobacter pylori infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 H pylori positive and 14 H pylori negative subjects. There was a four to six week washout period between the two pH recordings made in each subject after one week courses of placebo or omeprazole, 20 mg daily. During placebo, median 24 hour pH values were not different in the corpus (H pylori positive = 1.5, negative = 1.4; p = 0.9) or antrum (H pylori positive = 1.3, negative = 1.2; p = 0.1). However, during omeprazole treatment, median 24 hour pH values were higher in H pylori positive subjects, both in the corpus (H pylori positive = 5.5, negative = 4.0; p = 0.001) and antrum (H pylori positive = 5.5, negative = 3.5; p = 0.0004). During placebo treatment, the only difference between the two groups was a higher later nocturnal pH in the antrum in the H pylori positive group. During omeprazole treatment, gastric pH was higher both in the corpus and in the antrum in the H pylori positive group for all periods, except for mealtime in the corpus. These data indicate that omeprazole produces a greater decrease in gastric acidity in subjects with H pylori infection than in those who are H pylori negative. It is not, however, known whether there is a causal relationship between H pylori infection and increased omeprazole efficacy.

Download full-text


Available from: David Armstrong, Jun 24, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Proton-pump inhibitors (PPIs) are the drugs of choice for the treatment of gastroesophageal reflux disease (GERD). Esomeprazole is the latest PPI and was developed as the S-isomer of omeprazole as an attempt to improve its pharmacokinetic properties. Esomeprazole has been reported to have a somewhat higher potency in acid inhibition than other PPIs. Despite some controversy, data from clinical trials and meta-analyses indicate that esomeprazole 40 mg od for up to 8 weeks provided higher rates of healing of erosive GERD and a greater proportion of patients with sustained resolution of heartburn, than omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg od. Esomeprazole 20 mg od has also been shown to be more effective in maintaining healing of erosive GERD compared with lansoprazole 15 mg od or pantoprazole 20 mg od. However, it is not clear whether these statistically significant differences are of major clinical importance. Esomeprazole 20 mg od is superior to placebo for treatment of non-erosive reflux disease (NERD) but clinical trials have not shown any significant differences in efficacy between esomeprazole 20 mg and omeprazole 20 mg or pantoprazole 20 mg od. Lastly, although esomeprazole treatment in GERD has been reported to result in improvement of health-related quality of life (QoL) indices, no clinical trials have evaluated the possible differential effects of different PPIs on QoL in GERD.
    Therapeutics and Clinical Risk Management 09/2007; 3(4):653-63. · 1.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Omeprazole with amoxycillin has been used to treat Helicobacter pylori infection. It was speculated that omeprazole-induced hypoacidity enhances the antibacterial activity of amoxycillin. Limited information exists about intragastric pH and bioavailability of amoxycillin during combination therapy. No data are available about possible effects of the antibiotic on the pharmacokinetics and pharmacodynamics of omeprazole. The study was performed in a three-way cross-over double-blind design. After a run-in period on placebo with a baseline intragastric pH-metry, 24 H. pylori-positive healthy subjects were randomly dosed with amoxycillin 750 mg b.d. + placebo, amoxycillin 750 mg b.d. + omeprazole 40 mg b.d. and omeprazole 40 mg b.d. + placebo for 5 days. On the last day of each regimen intragastric pH-metries were performed, and blood samples taken for omeprazole and amoxycillin serum profiles. Amoxycillin monotherapy had no acid-inhibiting effect. Median pH during combined dosing was significantly lower, compared to omeprazole monotherapy (P < 0.01). Mean serum concentrations of omeprazole and amoxycillin given alone or in combination were not different. High-dose omeprazole does not alter the pharmacokinetics of amoxycillin. The significantly lower intragastric pH during combination therapy might be due to the H. pylori-suppressive effect of this treatment.
    Alimentary Pharmacology & Therapeutics 07/1996; 10(3):295-301. DOI:10.1111/j.0953-0673.1996.00295.x · 5.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a continuation of the debate on the management of dyspepsia while the role of Helicobacter pylori in duodenal ulcer disease is being questioned with renewed vigor, specifically in the United States. The interaction of NSAIDs and H. pylori provided some interesting, if at times confusing, literature while the debate on the safety of long-term acid suppression remained unresolved. There were some interesting developments with regard to therapeutic agents during this period. A fourth proton pump inhibitor was introduced to the market while cisapride, a drug previously considered safe, was effectively withdrawn from the North American market because of safety concerns. More data on the COX-1-sparing agents became available, and their impressive gastrointestinal safety profile was confirmed. It was noted, however, that the incidence of dyspepsia, experienced by users of these drugs, may remain a problem.
    Current Opinion in Gastroenterology 12/2000; 16(6):489-94. DOI:10.1097/00001574-199611000-00005 · 3.66 Impact Factor